STOCK TITAN
  1. Home
  2. News
  3. BMY

Repertoire® Immune Medicines and Bristol Myers Squibb Announce Multi-Year Strategic Collaboration to Develop Tolerizing Vaccines for Autoimmune Diseases

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Positive)
Tags
Rhea-AI Summary

Repertoire® Immune Medicines has announced a multi-year strategic collaboration with Bristol Myers Squibb (BMY) to develop tolerizing vaccines for up to three autoimmune diseases. As part of the agreement, Repertoire will receive an upfront payment of $65 million and is eligible to receive up to $1.8 billion for achieving development, regulatory, and commercial milestones, in addition to receiving tiered royalties. The collaboration aims to develop efficacious, selective, and durable treatments for patients suffering from autoimmune disease by resetting the immune system. Repertoire will lead all activities through development candidate nomination, while BMS will lead clinical development, regulatory affairs, and commercialization of the tolerizing vaccines under an exclusive worldwide license. The collaboration combines Repertoire's leading DECODE™ platform with BMS's expertise in developing and commercializing innovative immune medicines.

Repertoire® Immune Medicines ha annunciato una collaborazione strategica pluriennale con Bristol Myers Squibb (BMY) per sviluppare vaccini tollerizzanti per fino a tre malattie autoimmuni. Come parte dell'accordo, Repertoire riceverà un pagamento anticipato di 65 milioni di dollari e potrà ricevere fino a 1,8 miliardi di dollari per il raggiungimento di traguardi sviluppo, regolatori e commerciali, oltre a royalty scalari. La collaborazione mira a sviluppare trattamenti efficaci, selettivi e duraturi per i pazienti affetti da malattie autoimmuni tramite il reset del sistema immunitario. Repertoire guiderà tutte le attività fino alla nomina del candidato allo sviluppo, mentre BMS guiderà lo sviluppo clinico, gli affari regolatori e la commercializzazione dei vaccini tollerizzanti con una licenza esclusiva a livello mondiale. La collaborazione unisce la piattaforma DECODE™ leader di Repertoire con l'esperienza di BMS nello sviluppo e nella commercializzazione di medicine immunitarie innovative.
Repertoire® Immune Medicines ha anunciado una colaboración estratégica de varios años con Bristol Myers Squibb (BMY) para desarrollar vacunas tolerizantes para hasta tres enfermedades autoinmunes. Como parte del acuerdo, Repertoire recibirá un pago inicial de 65 millones de dólares y podría recibir hasta 1.8 mil millones de dólares al alcanzar hitos de desarrollo, regulación y comerciales, además de recibir regalías escalonadas. La colaboración tiene como objetivo desarrollar tratamientos eficaces, selectivos y duraderos para pacientes que sufren de enfermedades autoinmunes al reiniciar el sistema inmunológico. Repertoire liderará todas las actividades hasta la nominación del candidato de desarrollo, mientras que BMS liderará el desarrollo clínico, los asuntos regulatorios y la comercialización de las vacunas tolerizantes bajo una licencia exclusiva mundial. La colaboración combina la plataforma líder DECODE™ de Repertoire con la experiencia de BMS en el desarrollo y comercialización de medicinas inmunes innovadoras.
Repertoire® Immune Medicines는 Bristol Myers Squibb (BMY)과 함께 최대 세 가지 자가면역 질환에 대한 내성 백신을 개발하기 위한 다년간의 전략적 협력을 발표하였습니다. 협약에 따라 Repertoire는 6500만 달러의 선불금을 받게 되며, 개발, 규제 및 상업적 이정표를 달성하여 최대 18억 달러를 받을 자격이 있으며, 차등 로열티도 받게 됩니다. 이 협력은 자가면역 질환을 앓고 있는 환자들을 위해 면역 체계를 재설정함으로써 효과적이고 선택적이며 지속 가능한 치료법을 개발하는 것을 목표로 합니다. Repertoire는 개발 후보 지명까지 모든 활동을 주도할 것이며, BMS는 전 세계적으로 독점적인 라이선스 하에 내성 백신의 임상 개발, 규제 사항 및 상업화를 주도할 것입니다. 이 협력은 Repertoire의 선도적인 DECODE™ 플랫폼과 BMS의 혁신적인 면역 의학 개발 및 상업화에 대한 전문 지식을 결합하였습니다.
Repertoire® Immune Medicines a annoncé une collaboration stratégique de plusieurs années avec Bristol Myers Squibb (BMY) pour développer des vaccins tolérisants pour jusqu'à trois maladies auto-immunes. Dans le cadre de l'accord, Repertoire recevra un paiement initial de 65 millions de dollars et pourrait recevoir jusqu'à 1,8 milliard de dollars en atteignant des jalons de développement, réglementaires et commerciaux, en plus de recevoir des royalties échelonnées. La collaboration vise à développer des traitements efficaces, sélectifs et durables pour les patients souffrant de maladies auto-immunes en réinitialisant le système immunitaire. Repertoire dirigera toutes les activités jusqu'à la nomination du candidat au développement, tandis que BMS dirigera le développement clinique, les affaires réglementaires et la commercialisation des vaccins tolérisants sous une licence exclusive mondiale. La collaboration combine la plateforme DECODE™ leader de Repertoire avec l'expertise de BMS dans le développement et la commercialisation de médicaments immunitaires innovants.
Repertoire® Immune Medicines hat eine mehrjährige strategische Zusammenarbeit mit Bristol Myers Squibb (BMY) bekanntgegeben, um tolerierende Impfstoffe für bis zu drei Autoimmunerkrankungen zu entwickeln. Im Rahmen der Vereinbarung wird Repertoire eine Vorauszahlung von 65 Millionen Dollar erhalten und ist berechtigt, bis zu 1,8 Milliarden Dollar für das Erreichen von Entwicklungs-, Regulierungs- und Vermarktungsmeilensteinen zu erhalten, zusätzlich zu gestaffelten Lizenzgebühren. Die Zusammenarbeit zielt darauf ab, wirksame, selektive und dauerhafte Behandlungen für Patienten mit Autoimmunerkrankungen durch das Zurücksetzen des Immunsystems zu entwickeln. Repertoire wird alle Aktivitäten bis zur Nominierung des Entwicklungskandidaten leiten, während BMS die klinische Entwicklung, regulatorische Angelegenheiten und die Vermarktung der tolerierenden Impfstoffe unter einer exklusiven weltweiten Lizenz leiten wird. Die Zusammenarbeit vereint Repertoires führende DECODE™-Plattform mit der Expertise von BMS in der Entwicklung und Vermarktung innovativer Immunmedikamente.
Positive
  • Multi-year strategic collaboration with BMY to develop tolerizing vaccines for autoimmune diseases
  • Upfront payment of $65 million and eligible for up to $1.8 billion for achieving milestones and royalties
  • Aims to develop efficacious, selective, and durable treatments for patients suffering from autoimmune diseases
  • Repertoire to lead all activities up to development candidate nomination, while BMS to lead clinical development, regulatory affairs, and commercialization
  • Combines Repertoire's DECODE platform with BMS's expertise in developing and commercializing innovative immune medicines
Negative
  • None.

Collaboration combines Repertoire's industry leading DECODE™ platform that uniquely maps the immune synapse to develop T cell targeted immune medicines with Bristol Myers Squibb's world-leading expertise in developing and commercializing innovative immune medicines

Repertoire will receive an upfront payment of $65 million and is eligible to receive up to $1.8 billion in milestone and other payments and tiered royalties

CAMBRIDGE, Mass., April 29, 2024 /PRNewswire/ -- Repertoire® Immune Medicines, a biotechnology company pioneering the discovery and development of programmable T cell targeted immune medicines, announced today that it has entered a multi-year strategic collaboration with Bristol Myers Squibb (NYSE: BMY) to develop tolerizing vaccines for up to three autoimmune diseases. The collaboration aims to develop efficacious, selective, and durable treatments for patients suffering from autoimmune disease by resetting the immune system.

Under the terms of the agreement, Repertoire will receive an upfront payment of $65 million, and up to $1.8 billion for achieving development, regulatory and commercial milestones in addition to receiving tiered royalties.

Repertoire will lead all activities through to development candidate nomination, while BMS will lead clinical development, regulatory affairs, and commercialization of the tolerizing vaccines under an exclusive world-wide license. Repertoire will utilize its T cell receptor (TCR)-epitope discovery platform, DECODE, and its proprietary lipid nanoparticle delivery technology to discover and develop the tolerizing vaccine development candidates. In addition, it will deploy DECODE to monitor immune responses to the tolerizing vaccines in patients during clinical development to provide key insights into the pharmacodynamic effect of the vaccines.

"This agreement is a recognition of the transformative power of Repertoire's DECODE platform to discover and develop programmable T cell targeted immune medicines," said Torben Straight Nissen, Ph.D., CEO of Repertoire and Executive Partner of Flagship Pioneering. "We are excited to collaborate with Bristol Myers Squibb to combine their leadership in immunology with our unique ability to discover key disease-associated epitopes in patients with autoimmune diseases. This collaboration enables us to serve patients suffering from autoimmune diseases by translating our DECODE discoveries into potentially transformative medicines that address the underlying cause of their disease."     

"Bristol Myers Squibb strives to change the treatment paradigm for patients with autoimmune and immune-mediated diseases with a commitment to the discovery and development of transformational medicines," said Francisco Ramírez-Valle, M.D., Ph.D., senior vice president and head of the Immunology & Cardiovascular Thematic Research Center at Bristol Myers Squibb. "Our collaboration with Repertoire aims to selectively reset the immune system, reflecting a key component of our immunology research strategy, which we believe may offer long term benefit while mitigating unintended consequences associated with broad immune suppression."

About Repertoire® Immune Medicines

Repertoire Immune Medicines is a biotechnology company dedicated to creating treatments for diseases based on the power of the human T cell repertoire to eliminate cancer cells, target pathogens, and regulate immune function in autoimmune disease.

The company's proprietary DECODE™ platform provides a comprehensive understanding of the interactions between T cell receptors and their antigens in disease. DECODE uniquely elucidates the entire immune synapse, including the T-cell receptor-epitope pairs that defines it, the HLA context, and the T cell phenotype. This capability enables the creation of new and potentially transformative classes of immune-based medicines. Repertoire believes the ability to decipher these interactions represents one of the greatest opportunities for innovation in medical science. The company is utilizing the discoveries from DECODE to design and develop novel immune therapies for multiple therapeutic areas, such as autoimmune diseases, infectious diseases, and cancer.

Repertoire was founded in 2019 by Flagship Pioneering. Its team operates from sites in Cambridge, Massachusetts and Zurich. To learn more about Repertoire, please visit our website: www.repertoire.com and follow us on LinkedIn and Twitter.

Media Contacts

press@flagshippioneering.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/repertoire-immune-medicines-and-bristol-myers-squibb-announce-multi-year-strategic-collaboration-to-develop-tolerizing-vaccines-for-autoimmune-diseases-302127861.html

SOURCE Repertoire Immune Medicines

FAQ

What is the collaboration between Repertoire and Bristol Myers Squibb about?

The collaboration is focused on developing tolerizing vaccines for up to three autoimmune diseases, with Repertoire receiving an upfront payment of $65 million and being eligible for up to $1.8 billion in milestone and other payments, in addition to receiving tiered royalties.

What will Repertoire focus on in the collaboration?

Repertoire will lead all activities through to development candidate nomination.

What will Bristol Myers Squibb focus on in the collaboration?

BMS will lead clinical development, regulatory affairs, and commercialization of the tolerizing vaccines under an exclusive world-wide license.

What technologies will Repertoire utilize in developing the tolerizing vaccines?

Repertoire will utilize its T cell receptor (TCR)-epitope discovery platform, DECODE, and its proprietary lipid nanoparticle delivery technology to discover and develop the tolerizing vaccine development candidates.

Who will collaborate to monitor immune responses to the tolerizing vaccines in patients during clinical development?

Repertoire will deploy DECODE to monitor immune responses to the tolerizing vaccines in patients during clinical development.

Stock BMY logo
Bristol-Myers Squibb Company

NYSE:BMY

BMY Rankings

#133 Ranked by Market Cap
#4058 Ranked by Stock Gains
#541 Ranked by Dividends

BMY Latest News

May 16, 2024
New Four-Year Sotyktu (deucravacitinib) Data Demonstrate Durable Response Rates and Consistent Safety in Moderate-to-Severe Plaque Psoriasis
May 15, 2024
Bristol Myers Squibb’s CAR T Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma
May 10, 2024
Bristol Myers Squibb Provides Update on Phase 3 CheckMate -73L Trial
May 7, 2024
Bristol Myers Squibb to Participate in Upcoming Investor Conferences
May 6, 2024
U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase)

BMY Stock Data

90.31B
2.02B
0.1%
78.93%
1.73%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
PRINCETON

About BMY

The Bristol-Myers Squibb Company is an American multinational pharmaceutical company. Headquartered in New York City, BMS is one of the worlds largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest U.S. corporations. For fiscal 2022, it had a total revenue of $46.2 billion.